Label-free LC-MS analysis of HER2+ breast cancer cell line response to HER2 inhibitor treatment

BACKGROUND: Human epidermal growth-factor receptor (HER)-2 is overexpressed in 25 % of breast-cancers and is associated with an aggressive form of the disease with significantly shortened disease free and overall survival. In recent years, the use of HER2-targeted therapies, monoclonal-antibodies an...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Luca, Alessio, Henry, Michael, Meleady, Paula, O’Connor, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4524286/
https://www.ncbi.nlm.nih.gov/pubmed/26238995
http://dx.doi.org/10.1186/s40199-015-0120-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4524286/
https://www.ncbi.nlm.nih.gov/pubmed/26238995
http://dx.doi.org/10.1186/s40199-015-0120-y

Ejemplares similares